18 and older, any sex, with Dentin Hypersensitivity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Pain From Baseline Immediately After Application of Test Product.Primary· Base line and immediately after application (within 15 minutes post-treatment).
Change in sensitivity as assessed using a Visual Analog Scale (VAS, 0 - 100 mm) immediately after exposure to air stimulus relative to baseline.
The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.
Group
Value
95% CI
3M™ Clinpro™ Fluoride Aqueous Solution
8.9
± 10.26
3M™ Vanish™
8.6
± 8.41
Change in Pain From Baseline 24 Hours Post Application of Test Product.Primary· Baseline and 24 hours post-treatment
This is a co-primary endpoint
Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 24 hours after exposure to air stimulus relative to baseline.
The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.
Group
Value
95% CI
3M™ Clinpro™ Fluoride Aqueous Solution
12.8
± 10.57
3M™ Vanish™
11.5
± 9.43
Change in Pain From Baseline 7 Days Post Application of Test Product.Secondary· Baseline and 7 days post-treatment
Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 7 days after exposure to air stimulus relative to baseline.
The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.
Group
Value
95% CI
3M™ Clinpro™ Fluoride Aqueous Solution
14.6
± 13.45
3M™ Vanish™
12.9
± 11.45
Change in Pain From Baseline 21 Days Post Application of Test Product.Secondary· Baseline and 21 days post-treatment
Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 21 days after exposure to air stimulus relative to baseline.
The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.
Group
Value
95% CI
3M™ Clinpro™ Fluoride Aqueous Solution
18.6
± 13.69
3M™ Vanish™
16.4
± 12.47
Change in Pain From Baseline 30 Days Post Application of Test Product.Secondary· Baseline and 30 days post-treatment
Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 30 days after exposure to air stimulus relative to baseline.
The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.
Group
Value
95% CI
3M™ Clinpro™ Fluoride Aqueous Solution
22.1
± 16.81
3M™ Vanish™
20.3
± 15.05
Sponsor's own description
The goal of this clinical trial is to evaluate the effect of 3M™ Clinpro™ Fluoride Aqueous Solution (experimental) on Dentin Hypersensitivity (DHS) in comparison to 3M™ Vanish™ (commercialized, control\] in patients who have DHS.
Participants will be asked to complete the following activities:
Undergo a pre-treatment washout period for 3- to 6-weeks (± 4 days) post-enrollment. During this time, the Subject is to only use the provided oral hygiene products.
Hypersensitivity will be assessed prior to (baseline) and immediately after sample application.
Subject will be asked to come to the facility for hypersensitivity assessments at 24 hours, 7 days, and 30 days after the treatment visit.
Researchers will compare 3M™ Clinpro™ Fluoride Aqueous Solution to 3M™ Vanish™ to evaluate if the effect of Clinpro™ on DHS treatment is non-inferior to Vanish™.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Other recruiting trials for Dentin Hypersensitivity
Currently open trials in the same condition.
NCT07431736 — Laser Therapy for Dentin Hypersensitivity
· NA
· active not recruiting
NCT07069127 — Hydroxyapatite-Based Home Treatment for Dentin Sensitivity in Celiac Patients
· NA
· recruiting
NCT07113847 — Effectiveness of Resin-Based Desensitizer and Laser, Compared to Fluoride Varnish in Management of Dentine Hypersensitiv
· Phase 2, PHASE3
· active not recruiting
Other Solventum US LLC trials
Trials by the same sponsor.
NCT05748392 — 3M Veraflo™ Cleanse Choice Complete™ (VFCCC) Clinical Study
· NA
· withdrawn
NCT05361746 — Scotchbond Universal Plus Compared to Scotchbond Universal With Filtek Universal Restorative to Restore Class V NCCLs
· NA
· active not recruiting
NCT05248204 — Scotchbond Universal Plus Compared to Scotchbond Universal for Posterior Class I & II Restorations With Filtek Universal
· NA
· completed
NCT04906512 — Comparing CHG I.V. Securement Dressing With Transparent Dressing for Evaluation of Antimicrobial Efficacy
· NA
· terminated
NCT04869696 — Medical Adhesive Repeat Application Study
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Solventum US LLC
Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05768373.